A new study has shown that sofosbuvir (SOF) base regimens are effective and well tolerated by hepatitis C and HIV co-infected, cirrhotic patients.
This was revealed today at the International Liver Congress 2015.
This is great news as this patient group is considered difficult to treat and have high mortality rate.
142 patients of different hepatitis virus (HCV) genotypes were initiated on SOF based regimens for the study.
Adverse effects reported in 42 patients (digestive 10 percent, anaemia, 19 percent, asthemia 24 percent, others 48 percent).
Treatment was stopped on 3 patients and dose adjusted in 13.
The results showed that direct acting antivirals (DAAS) such as SOF based regimens are effective and tolerated in HIV-HCV co-infected patients but surveillance for liver related effects must continue in these patients.
0 Yorumlar